<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03165227</url>
  </required_header>
  <id_info>
    <org_study_id>1366-0004</org_study_id>
    <secondary_id>2014-004541-27</secondary_id>
    <nct_id>NCT03165227</nct_id>
  </id_info>
  <brief_title>This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)</brief_title>
  <official_title>Randomised, Double-blind, Placebo-controlled Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Multiple Rising Oral Doses of BI 685509 Over 28 Days in Male and Female Patients With Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this trial is the safety and tolerability of 4 multiple rising oral
      doses of BI 685509 over 28 days in male and female patients with Diabetic Nephropathy (DN) as
      adjunctive to Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker
      (ARB). Another objective is the change in Urine Albumin Creatinine Ratio (UACR), an important
      diagnostic marker of nephropathy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with drug related Adverse Events (AEs)</measure>
    <time_frame>Up to 35 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in log transformed Urine albumin creatinine ratio (UACR) measured in morning void urine</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in log transformed Urine albumin creatinine ratio (UACR) measured in 24-hour urine</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>BI 685509 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 685509 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 685509 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 685509 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 685509</intervention_name>
    <description>Taken orally</description>
    <arm_group_label>BI 685509 Dose 1</arm_group_label>
    <arm_group_label>BI 685509 Dose 2</arm_group_label>
    <arm_group_label>BI 685509 Dose 3</arm_group_label>
    <arm_group_label>BI 685509 Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Taken orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated written informed consent in accordance with ICH-GCP and local
             legislation prior to admission to the trial

          -  Male or postmenopausal (last menstruation ≥ 2 years ago) patients, or female patients
             who are sterilized by either hysterectomy, bilateral salpingectomy and/or bilateral
             oophorectomy. Male patients with partners of child-bearing potential must be willing
             to use condoms from the time of the first intake of study drug until follow-up.

          -  eGFR (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) ≥ 20 and &lt;
             60 ml/min/1.73 m2 at Visit 1 measured by the central laboratory and no planned start
             of renal replacement therapy during the trial

          -  UACR ≥ 200 and &lt;3500 mg/g in spot urine (midstream urine sample) at Visit 1 measured
             by the central laboratory

          -  Treatment with either ACEi or ARB, stable dose since ≥ 4 weeks before Visit 1 with no
             planned change of the therapy

          -  Patients with type 1 or type 2 diabetes mellitus, diagnosed before informed consent
             and treated with insulin, glucagon-like peptide (GLP) 1 agonists and/or oral
             antidiabetic medication. Treatment should have been unchanged (investigator's
             judgment) within 4 weeks before Visit 1 and until randomisation

          -  Glycated Haemoglobin (HbA1c) ≥ 6.5% and &lt; 10.0% at Visit 1 measured by the central
             laboratory

          -  Seated Systolic Blood Pressure (SBP) ≥ 110 and ≤ 180 mmHg and Diastolic Blood Pressure
             (DBP) ≥ 70 and ≤ 110 mmHg at Visit 1

          -  Age at screening ≥ 18 years for male and permanently sterilized female patients and ≥
             45 years for postmenopausal female patients

          -  Body Mass Index (BMI) ≥ 18.5 and &lt; 45 kg/m2

          -  Successful ABPM reading before randomisation, upper arm circumference within the
             circumference level of the cuff size of either ABPM and/or BP measurement device used
             in the study

        Exclusion Criteria:

          -  Treatment with phosphodiesterase inhibitors, nitrates or riociguat, from screening
             (Visit 1) or within 5 half-lives before randomisation whatever is earlier. Concomitant
             treatment from screening (Visit 1) with glitazones, and repaglinide.

          -  Any laboratory value more than 3 times above upper limit of normal (ULN) at screening
             (Visit 1) or any other laboratory value outside the reference range and clinically
             relevant (for safe participation) in the investigator judgment

          -  Confirmed non-diabetic renal disease in the opinion of investigator

          -  Any other medical condition that in the investigator's opinion poses a safety risk for
             the patient or may interfere with the study objectives including

               -  symptomatic heart failure (NYHA III/IV),

               -  known history of tachycardia and/or atrial fibrillation

               -  clinically relevant arrhythmias

               -  coronary heart disease not compensated by medical treatment (supine pulse rate
                  &gt;70 beats per minute, existing angina pectoris)

               -  &lt;6 months after myocardial infarction.

          -  Medical history of cancer or treatment for cancer in the last two years prior to Visit
             1 (except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of
             uterine cervix, and prostatic cancer of low grade [T1 or T2] is exempted)

          -  Surgery or trauma with significant blood loss (investigator's judgement) within the
             last 3 months prior to informed consent or significant blood donation (investigator's
             judgement) within four weeks prior to first administration of study medication or
             planned during the trial

          -  Previous enrolment in this trial

          -  Currently enrolled in another investigational device or drug study, i.e., less than 30
             days since ending another investigational device or drug study(s), or receiving other
             investigational treatment(s)

          -  Chronic alcohol or drug abuse or any condition that, in the investigator's opinion,
             makes them an unreliable study subject or unlikely to complete the trial

          -  Women of childbearing potential

          -  Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>California Institute of Renal Research</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Fadda</last_name>
      <phone>+001 (619) 461-3894</phone>
      <email>gfadda@cairr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Creekside Endocrine Associates, PC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonard Zemel</last_name>
      <phone>+001 (303) 394-2888</phone>
      <email>zennylemel@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Innovative Research of West Florida, Inc.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Trevino</last_name>
      <phone>+001 (727) 584-8777</phone>
      <email>miguelt@innovativeresearchfl.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Center for Diabetes and Endocrine Care</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sam Lerman</last_name>
      <phone>+001 (954) 963-7100</phone>
      <email>slerman@diabetes-endocare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indago Research and Health Center</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Cardona</last_name>
      <phone>+001 (305) 825-6588</phone>
      <email>jcardona@indagoresearch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocean Blue Medical Research Center, Inc.</name>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Rondon</last_name>
      <phone>+001 (305) 885-8983</phone>
      <email>juan.rondon@obmedresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Marcus Research Clinic, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Idalia Acosta</last_name>
      <phone>+001 (305) 424-7420</phone>
      <email>iacosta@sanmarcusrc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research by Design, LLC</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60643</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Crawford</last_name>
      <phone>+001 (708) 952-4644</phone>
      <email>pcrawford@researchbd.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tulane University Hospital and Clinic</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivian Fonseca</last_name>
      <phone>+001 (504) 988-5044</phone>
      <email>vfonseca@tulane.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Louisiana Nephrology L.L.C.</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marwan Kaskas</last_name>
      <phone>+001 (318) 220-9792</phone>
      <email>marwankas@bellsouth.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scott Research, Inc.</name>
      <address>
        <city>Laurelton</city>
        <state>New York</state>
        <zip>11413</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Scott</last_name>
      <phone>+001 (718) 276-4750</phone>
      <email>dscott@scottresearch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington, LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Parker</last_name>
      <phone>+001 (910) 815-6108</phone>
      <email>dr.john.parker@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Institute of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Aronoff</last_name>
      <phone>+001 (214) 265-2137</phone>
      <email>researcharonoff@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Clinical Research Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Siddiqi</last_name>
      <phone>+001 (281) 650-1846</phone>
      <email>msiddiqi@hcratrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Advancement Center PLLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Pergola</last_name>
      <phone>+001 (210) 223-4444</phone>
      <email>ppergola@raparesearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Science Advancing Medicine Clinical Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sam Miller</last_name>
      <phone>+001 (210) 614-4800</phone>
      <email>sam@samcrc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>York Clinical Research, LLC</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Lovell</last_name>
      <phone>+001 (757) 373-9478</phone>
      <email>lovellmdfacp@yorkclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bonheiden - HOSP Imelda</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Vercammen</last_name>
      <phone>+32 (0)15 50 51 64</phone>
      <email>chris.vercammen@imelda.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brussels - UNIV UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Debroye</last_name>
      <phone>+32 (0)2 474 93 97</phone>
      <email>corinne.debroye@uzbrussel.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Edegem - UNIV UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe De Block</last_name>
      <phone>+32 (0)3 821 32 76</phone>
      <email>christophe.de.block@uza.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UNIV UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Lapauw</last_name>
      <phone>+32 (0)9 332 21 38</phone>
      <email>Bruno.Lapauw@uzgent.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Jandrain</last_name>
      <phone>+32 (0)4 366 83 06</phone>
      <email>bernard.jandrain@chu.ulg.ac.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jitka Rehorova</last_name>
      <phone>+420 532 223 828</phone>
      <email>Rehorova.Jitka@fnbrno.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SocraTec R&amp;D GmbH</name>
      <address>
        <city>Erfurt</city>
        <zip>99084</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Donath</last_name>
      <phone>493616020555</phone>
      <email>Frank.Donath@socratec-pharma.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CTC North GmbH &amp; Co. KG, Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Aberle</last_name>
      <phone>+49(40)741050085</phone>
      <email>aberle@uke.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hyperbaric and Wound Care Center of PR</name>
      <address>
        <city>Ponce</city>
        <zip>00780</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Sosa-Faria</last_name>
      <phone>+001 (713) 589-6400</phone>
      <email>jsosa@ccoreintl.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>May 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2017</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

